Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
September 19, 2019 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
September 17, 2019 08:10 ET
|
Helsinn Healthcare S.A.
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology The Award recognizes Patient Entrepreneurs demonstrating...
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020
August 29, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020 The Award recognizes Patient...
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
July 31, 2019 08:10 ET
|
Helsinn Healthcare S.A.
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP), and Helsinn, a Swiss...
Helsinn Investment Fund Announces First Exit
July 15, 2019 10:05 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Announces First Exit Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient...
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
June 26, 2019 01:00 ET
|
Helsinn Healthcare S.A.
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on...
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress
June 12, 2019 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress Symposium will explore the...
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
June 07, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology Cutaneous Lymphoma Meeting will update on latest developments...
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
June 01, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania ...
Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019
May 31, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019 The NEPA IV formulation was evaluated for safety in the AC setting. Lugano,...